Cost of a pharmacist-directed intervention to increase treatment of hypercholesterolemia

Pharmacotherapy

Volumn 24, Issue 8, 2004, Pages 1077-1083

  Hilleman, Daniel E ^a   Faulkner, Michele A ^a   Monaghan, Michael S ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Coronary heart disease; Hypercholesterolemia; Lipid lowering therapy; Pharmacist directed intervention; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST CONTROL; HEALTH CARE; HEALTH CARE COST; HEALTH EDUCATION; HEALTH PROGRAM; HEART INFARCTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; PHARMACIST; PHYSICIAN; SALARY; TRANSLUMINAL CORONARY ANGIOPLASTY;

CASE-CONTROL STUDIES; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MIDDLE AGED; PHARMACEUTICAL SERVICES; TREATMENT OUTCOME;

EID: 3543141099     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.11.1077.36145     Document Type: Article

References (40)

1. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999;12:711-17.
2. Pieper RM, Arnett DK, McGovern PG, Shahar E, Blackburn H, Luepker RV. Trends in cholesterol knowledge and screening and hypercholesterolemia awareness and treatment, 1980-1992. Arch Intern Med 1997;157:2326-32.
3. Pearson TA, Laurora I, Chu H, Kafanek S. The lipid treatment assessment project (L-TAP): a multi-center survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
4. Miller M, Byington R, Hunninghake D, Pitt B, Furberg CD. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Arch Intern Med 2000;160:343-7.
5. Lee TH, Cleeman JI, Grundy SM, et al. Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease. JAMA 2000;283:94-8.
6. Benner JS, Glynn RJ, Morgun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
7. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndrome. JAMA 2002;288:412-62.
8. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-31.
9. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-62.
10. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208-11.
11. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998;158:1238-44.
12. Harris DE, Record NB, Gipson GW, Pearson TA. Lipid lowering in a multidisciplinary clinic compared with primary physician management. Am J Cardiol 1998;81:929-32.
13. Hilleman DE, Monaghan MS, Ashby CR, Mashni JE, Wooley K, Amato CM. Physician-prompting statin therapy intervention improves outcomes in patients with coronary heart disease. Pharmacotherapy 2001;21:1415-21.
14. American Medical Association. Current procedural terminology 2004, standard edition. Chicago, IL: American Medical Association, 2004.
15. Randensky PW, Berliner E, Archer JW, Dournaux SF. Inpatient costs of major cardiovascular events. Am J Cardiovasc Drugs 2001:1:205-17.
16. Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000;132(10):769-79.
17. Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S (Scandinavian simvastatin survival study) trial. Diabetologia 1999:42(11):1293-301.
18. Herman WH, Alexander CM, Cook JR, et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes: findings from the Scandinavian simvastatin survival study. Diabetes Care 1999;22(11):1771-8.
19. Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996;78(4):409-14.
20. Elliot WJ, Weir DR. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am J Health-Syst Pharm 1999;56(17):1726-32.
21. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease: Scandinavian simvastatin survival study group. N Engl J Med 1997;336(5):332-6.
22. Nieto FJ, Alonso J, Chambless LE, et al. Population awareness and control of hypertension and hypercholesterolemia: the atherosclerosis risk in communities study. Arch Intern Med 1995;155:677-84.
23. Giles WH, Anda RF, Jones DH, et al. Recent trends in the identification and treatment of high blood cholesterol by physicians: progress and missed opportunities. JAMA 1993;269:1133-8.
24. Marcellina JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996;100:605-10.
25. Schectman G, Hiah J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996;100:197-204.
26. Brown S, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998;32:665-77.
27. Hunninghake D, Bakker-Arkema RG, Wigand JP, et al. Treating to meet NCEP-recommended LDL-cholesterol concentrations with atorvastatin, fluvastatin, lovastatin or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract 1998;47:349-56.
28. Koren MJ, Smith DG, Hunninghake DB, et al. The cost of reaching national cholesterol education program (NCEP) goals in hypercholesterolemic patients. Pharmacoeconomics 1998:14:49-70.
29. Smith DG, Leslie SJ, Szucs TD, et al. Cost of treating to a modified European Atherosclerosis Society LDL-C target. Clin Drug Invest 1999;17:185-93.
30. Jones PH, Davidson MH, Steih EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR [statin therapies for elevated lipid levels compared across doses to rosuvastatin] trial). Am J Cardiol 2003;92:152-60.
31. Haskell WL, Alderman EL, Fair JM, et al. Effects of interventional multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women in coronary artery disease: the Stanford coronary risk intervention project (SCRIP). Circulation 1994;89:975-90.
32. Fonarow GC, Gawlinski A, Moughrabi S, Tallest JH. Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program. Am J Cardiol 2001:87:819-22.
33. Becky N, Gerber J, Spivey-Miller S. A comparison of a pharmacist-managed lipid clinic to routine medical care in the treatment of hyperlipidemia [abstr]. Pharmacotherapy 1997;80:39H-44.
34. Furmaga EM. Pharmacist management of a hyperlipidemia clinic. Am J Hosp Pharm 1993;50:91-5.
35. Bozovich M, Rubino LM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving national cholesterol education program low-density lipoprotein goals. Pharmacotherapy 2000;20:1375-83.
36. Bluml BM, McKenney JM, Cziraky, MJ. Pharmaceutical care services and results in project IMPACT: hyperlipidemia. J Am Pharm Assoc 2000;40(2):157-65.
37. Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: The IMPROVE study. Pharmacotherapy 2000;20:1508-16.
38. Guthrie RM. The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clin Ther 2001;23:970-80.
39. Robinson JG, Conroy C, Wickemeyer WJ. A novel telephone-based system for management of secondary prevention to a low-density lipo-protein cholesterol ≤ 100 mg/dl. Am J Cardiol 2000;85:305-8.
40. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000;20:410-16.